Sutimlimab phase 3 placebo-controlled study in primary cold agglutinin disease without recent transfusion

Phase 3, randomised, double-blind trial of sutimlimab in cold agglutinin disease (CAD), sponsored by Sanofi. Primary endpoints: Percentage of participants with response and Number of participants with treatment-emergent adverse events and serious adverse events. Started Sep 2018; status: active, not recruiting.